The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Blinov D.E.

Peoples’ Friendship University of Russia

Kuhareva E.I.

Peoples’ Friendship University of Russia

Tarasova O.I.

Peoples’ Friendship University of Russia

Aleksandrova M.R.

Peoples’ Friendship University of Russia

Politidis R.R.

Peoples’ Friendship University of Russia

Gilbert’s syndrome may predict the favorable outcome of antiviral therapy in patients with HDV infection

Authors:

Blinov D.E., Kuhareva E.I., Tarasova O.I., Aleksandrova M.R., Politidis R.R.

More about the authors

Journal: Russian Journal of Evidence-Based Gastroenterology. 2022;11(1): 5‑12

DOI: 10.17116/dokgastro2022110115

Views: 1733

Downloaded: 63

Download PDF (RU)
Contact the author
Table of contents

GILBERT’S SYNDROME MAY PREDICT THE FAVORABLE OUTCOME OF ANTIVIRAL THERAPY IN PATIENTS WITH HDV INFECTION
GILBERT’S SYNDROME MAY PREDICT THE FAVORABLE OUTCOME OF ANTIVIRAL THERAPY IN PATIENTS WITH HDV INFECTION

To cite this article:

Blinov DE, Kuhareva EI, Tarasova OI, Aleksandrova MR, Politidis RR. Gilbert’s syndrome may predict the favorable outcome of antiviral therapy in patients with HDV infection. Russian Journal of Evidence-Based Gastroenterology. 2022;11(1):5‑12. (In Russ.)
https://doi.org/10.17116/dokgastro2022110115

 
Подписка 2025-2 (Russian Journal of Evidence-Based Gastroenterology)
МСФ на ЯМ
Close metadata

AIM

To assess the course of chronic HDV infection during therapy with nucleoside analogs in patients with Gilbert’s syndrome.

MATERIALS AND METHODS

The prospective study included 27 patients with chronic hepatitis D (CHD) observed at the Ogurtsov P.P. Liver Research Center (Moscow) from 2018 to 2021. Patients were prescribed antiviral therapy (HTP) — tenofovir 300 mg daily. Depending on Gilbert’s syndrome (GS), patients were divided into two groups. The dynamics of transaminase levels, the amount of HBsAg, HBV viral load, HDV RNA, and liver fibrosis were evaluated. The Wilcoxon, chi-squared, F-test, and odds ratio were used for statistical analysis.

RESULTS

In patients with chronic hepatitis D and Gilbert’s syndrome, a statistically significant decrease in the level of transaminases (p=0.04), HBsAg concentration (p<0.001), HBV DNA (p<0.001), and the risk of liver fibrosis progression by 2.3 times (OR=2.3, 95% CI 1.147—5.211; p<0.05) were observed after administration of tenofovir 300 mg daily.

CONCLUSION

Gilbert’s syndrome may predict the favorable outcome of tenofovir therapy in patients with HDV infection.

Keywords:

chronic hepatitis D
gilbert’s syndrome
liver fibrosis
nucleosides
tenofovir

Authors:

Blinov D.E.

Peoples’ Friendship University of Russia

Kuhareva E.I.

Peoples’ Friendship University of Russia

Tarasova O.I.

Peoples’ Friendship University of Russia

Aleksandrova M.R.

Peoples’ Friendship University of Russia

Politidis R.R.

Peoples’ Friendship University of Russia

Received:

08.12.2021

Accepted:

27.01.2022

List of references:

  1. Rizzetto M, Canese MG, Arico S, Crivelli O, Trepo C, Bonino F, Verme G. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut. 1977;18(12):997-1003. https://doi.org/10.1136/gut.18.12.997
  2. Isaeva OV, Kyuregyan KK. Viral hepatitis delta: an underestimated threat. Infekcionnye bolezni: novosti, mneniya, obuchenie. 2019;8(2):72-79. (In Russ.). https://doi.org/10.24411/2305-3496-2019-12010
  3. Hercun J, Koh C, Heller T. Hepatitis Delta. Gastroenterology Clinics of North America. 2020;49(2):239-252.  https://doi.org/10.1016/j.gtc.2020.01.004
  4. Wranke A, Heidrich B, Ernst S, Serrano BC, Caruntu FA, Curescu MG, Yalcin K, Gurel S, Zeuzem S, Erhardt A, Luth S, Papatheodoridis GV, Bremer B, Stift J, Grabowski J, Kirschner J, Port K, Cornberg M, Falk CS, Dienes HP, Hardtke S, Manns MP, Yurdaydin C, Wedemeyer H; HIDIT-2 Study Group. Anti-HDV IgM as a Marker of Disease Activity in Hepatitis Delta. PLoS ONE. 2014;9(7):e101002. https://doi.org/10.1371/journal.pone.0101002
  5. Volz T, Allweiss L, ḾBarek MB, Warlich M, Lohse AW, Pollok JM, Jörg M, Alexandrov A, Urban S, Jörg P, Lütgehetmann M, Dandri M. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. Journal of Hepatology. 2013;58(5):861-867.  https://doi.org/10.1016/j.jhep.2012.12.008
  6. Yurdaydin C, Keskin O, Kalkan Ç, Karakaya F, Çalişkan A, Karatayli E, Karatayli S, Bozdayi AM, Koh C, Heller T, Idilman R, Glenn JS. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study. Hepatology. 2018;67(4):1224-1236. https://doi.org/10.1002/hep.29658
  7. Bazinet M, Pântea V, Cebotarescu V, Cojuhari L, Jimbei P, Albrecht J, Schmid P, Le Gal F, Gordien E, Krawczyk A, Mijočević H, Karimzadeh H, Roggendorf M, Vaillant A. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial. The Lancet Gastroenterology and Hepatology. 2017;2(12):877-889.  https://doi.org/10.1016/s2468-1253(17)30288-1
  8. Ivashkin VT, Yushchuk ND, Maevskaya MV, Znojko OO, Dudina KR, Karetkina GN, Klimova EA, Maksimov SL, Martynov YuV, Maev IV, Pavlov ChS, Fedos’ina EA, Bueverov AO, Abdurahmanov DT, Malyshev NA, Nikitin IG, Mojsyuk YaG, Lapina TL, Truhmanov AS, Kozhevnikova GM, Zhdanov KV, Rahmanova AG, Chulanov VP, Shahgil’dyan IV, Syutkin VE, Bogomolov PO. Clinical recommendations of the Gastroenterological Association and the Russian Society for the Study of the Liver for the diagnosis and treatment of adult patients with hepatitis B. Rossijskij zhurnal gastroenterologii, gepatologii, koloproktologii. 2014;3:58-88. (In Russ.).
  9. Klinicheskij protokol diagnostiki i lecheniya «Hronicheskij gepatit B u vzroslyh». Protokol №77 Ministerstva zdravoohraneniya Respubliki Kazahstan. Accessed September 7, 2021. (In Russ.). https://diseases.medelement.com/disease/%D1%85%D1%80%D0%BE%D0%BD%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B8%D0%B9-%D0%B3%D0%B5%D0%BF%D0%B0%D1%82%D0%B8%D1%82-%D0%B2-%D1%83-%D0%B2%D0%B7%D1%80%D0%BE%D1%81%D0%BB%D1%8B%D1%85-2019/16388
  10. Schwertner HA, Vítek L. Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk: Possible protective effects and therapeutic applications of bilirubin. Atherosclerosis. 2008;198(1):1-11.  https://doi.org/10.1016/j.atherosclerosis.2008.01.001
  11. Stocker R, Yamamoto Y, McDonagh A, Glazer A, Ames B. Bilirubin is an antioxidant of possible physiological importance. Science. 1987;235(4792):1043-1046. https://doi.org/10.1126/science.3029864
  12. Bulmer AC, Blanchfield JT, Toth I, Fassett RG, Coombes JS. Improved resistance to serum oxidation in Gilbert’s syndrome: A mechanism for cardiovascular protection. Atherosclerosis. 2008; 199(2):390-396.  https://doi.org/10.1016/j.atherosclerosis.2007.11.022
  13. Radlović N, Leković Z, Mladenović M, Ristić D, Radlović V, Lekić V, Vuletić B, Djurdjević J, Gajić M. Gilbert’s syndrome in children-our experience Srpski Arhiv za Celokupno Lekarstvo. 2007;135(5-6):317-320.  https://doi.org/10.2298/sarh0706317r
  14. Landerer S, Kalthoff S, Paulusch S, Strassburg CP. UDP-glucuronosyltransferase polymorphisms affect diethylnitrosamine-induced carcinogenesis in humanized transgenic mice. Cancer Science. 2020;111(11):4266-4275. https://doi.org/10.1111/cas.14635
  15. Sena LA, Chandel NS. Physiological Roles of Mitochondrial Reactive Oxygen Species. Molecular Cell. 2012;48(2):158-167.  https://doi.org/10.1016/j.molcel.2012.09.025
  16. Luangmonkong T, Suriguga S, Mutsaers HAM, Groothuis GMM, Olinga P, Boersema M. Targeting Oxidative Stress for the Treatment of Liver Fibrosis. Reviews of Physiology, Biochemistry and Pharmacology. 2018;175:71-102.  https://doi.org/10.1007/112_2018_10
  17. Rosca MG, Vazquez EJ, Chen Q, Kerner J, Kern TS, Hoppel CL. Oxidation of Fatty Acids Is the Source of Increased Mitochondrial Reactive Oxygen Species Production in Kidney Cortical Tubules in Early Diabetes. Diabetes. 2012;61(8):2074-2083. https://doi.org/10.2337/db11-1437
  18. EASL European Association for the Study of the Liver. EASL European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. Journal of Hepatology. 2017;67(2):370-398.  https://doi.org/10.1016/j.jhep.2017.03.021
  19. Pavlov ChS, Glushenkov DV, Ivashkin VT. Sovremennye vozmozhnosti elastometrii, fibro- i akti-testa v diagnostike fibroza pecheni. Rossijskij zhurnal gastroenterologii, gepatologii, koloproktologii. 2008;4:43-52 (In Russ.).
  20. Soriano V, Vispo E, Sierra-Enguita R, Mendoza Cd, Fernández-Montero JV, Labarga P, Barreiro P. Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients. AIDS. 2014;28:2389-2394. https://doi.org/10.1097/qad.0000000000000417
  21. Wedemeyer H, Bogomolov P, Blank A, Allweiss L, Dandri-Petersen M, Bremer B, Voronkova N, Schöneweis K, Pathil A, Burhenne J, Haag M, Schwab M, Haefeli WE, Wiesch JSZ, Alexandrov A, Urban S. Final results of a multicenter open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with tenofovir in patients with chronic HBV/HDV infection. Journal of Hepatology. 2018;68(S3). https://doi.org/10.1016/S0168-8278(18)30224-1

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.